Pharmacogenomics and adverse drug reactions: The case of statins

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 10, 2011, Pages 1499-1509

  Giorgi, Mariano A ^a,b   Caroli, Christian ^a   Arazi, Hernán Cohen ^a   Di Girolamo, Guillermo ^c,d  

^a FLENI   (Argentina)

^b UNIVERSIDAD AUSTRAL   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d FAVALORO UNIVERSITY   (Argentina)

Author keywords

adverse drug reactions; muscular toxicity; pharmacogenomics; statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; ORGANIC ANION TRANSPORTER 2; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

DOSE RESPONSE; DRUG SAFETY; DRUG TRANSPORT; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; IC 50; LIVER TOXICITY; MUSCLE CRAMP; MUSCLE TOXICITY; MYALGIA; MYOPATHY; PHARMACOGENOMICS; REVIEW; RHABDOMYOLYSIS;

GENETIC MARKERS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MUSCULAR DISEASES; ORGANIC ANION TRANSPORTERS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SIMVASTATIN;

EID: 79958736753     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.563734     Document Type: Review

References (95)

1. International human genome sequencing consortium. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921
2. Daly AK. Pharmacogenetics and human genetic polymorphisms. Biochem J 2010;429:435-49
3. Tohkin M, Ishiguro A, Kaniwa N, et al. Prediction of severe adverse drug reactions using pharmacogenetic biomarkers. Drug Metab Pharmacokinet 2010;25(2):122-33
4. Bai JP. Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics. Drug Metab Pharmacokinet 2010;25(1):62-71
5. Malhey RW, Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton LL, Lazo JS, Parker KL, editors, Goodman & Gilmans the pharmacological basis of therapeutics. 11th edition. McGraw Hill, New York; 2006. p. 933-66
6. Cholesterol Treatment Trialists (CTT) Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
7. Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovascular mortality and events with statin treatments. A network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52(22):1769-81
8. Ridker PM, Danielson E, Fonseca FAH, et al.; for the Jupiter Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
9. Yusuf S, Lonn E, Bosch J. Lipid lowering for primary prevention. Lancet 2009;373:1152-5
10. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39 (Pubitemid 38924592)
11. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur J Cardiovasc Prev Rehabil 2007;14(Suppl 2):E1-40
12. Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-90 (Pubitemid 350137473)
13. Strandberg TE, Pyorala PK, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004;364:771-7 (Pubitemid 39165096)
14. Long-term eff ectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002;359:1379-87
15. Davidson MH, Clark JA, Glass LM, et al. Statin safety: an appraisal from the adverse events reporting system. Am J Cardiol 2006;97(Suppl):32C-43C
16. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
17. Clark JM. The epidemiology of non-alcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40(Suppl 1):S5-10 (Pubitemid 44309537)
18. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver function tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-22
19. Bader T. Liver test are irrelevant when prescribing statins. Lancet 2010;376:1882-3
20. Kinlay S, Schwartz GC, Olsson Ag, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study. Circulation 2004;110:386-91 (Pubitemid 38993846)
21. Newman C, Tsai J, Szrarek, et al. Comparative safety of atorvastatin 80 mg versus 10 mg deriverd from analysis of 49 compared trials in 14,236 patients. Am J Cardiol 2006;97:61-7 (Pubitemid 41828124)
22. deLemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs. delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16 (Pubitemid 39223221)
23. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf 2007;6(6):673-84. (Pubitemid 351308279)
24. Thompson PD, Clarkson PM, Rosenson PS. An assessment of statin safety from muscle experts. Am J Cardiol 2006;97(Suppl):69C-76C
25. Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72 (Pubitemid 34833176)
26. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163:553-64. (Pubitemid 36314342)
27. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009;150:858-68
28. Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolarebility of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002;105:2341-6 (Pubitemid 34556383)
29. Garcia-Rodriguez LA, Gonzalez-Perez A, Stang MR, et al. The safety of rosuvastatin in comparison with other statins in over 25000 statin users in the Saskatchewan Health Databases. Pharmacoepidemiol Drug Saf 2008;17:953-61
30. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32225 diabetic and non-diabetic patients. Clin Ther 2007;29:1761-70 (Pubitemid 47494553)
31. Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis 2010;210:337-43
32. Ho PM, Magid DJ, Shetterly SM, et al. Medication non-adherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008;155:772-9 (Pubitemid 351410514)
33. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther 2005;19(6):403-14 (Pubitemid 43228152)
34. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006;34:153-62 (Pubitemid 44167798)
35. Vladutiu GD. Genetic predisposition to statin myopathy. Curr Opin Rheumatol 2008;20:648-55
36. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 2010;87(1):130-3
37. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007;8:787-802 (Pubitemid 47288978)
38. Atorvastatin, Lovastatin, simvastatin pharmacokinetics. Pharmgkb.org Available from: www.pharmgkb.org/do/serve? objId=PA145011109&objCIs=pathway. [Last accessed 20 November 2010]
39. McKenney JA, Ganz P, Wiggins BS, et al. Statins. In: Ballantyne CM, editor, Clinical Lipidology: a companion to Braunwalds Heart Disease. Saunders Elsevier, Philadelphia; 2009. p. 253-80
40. Konig J, Cui Y, Nies AT, et al. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J physiol Gastrointest Liver Physiol 2000;278:156-64
41. Robey RW, To KK, Polgar O, et al. ABCG2: a perspective. Adv Drug Deliv Rev 2009;61(1):1-3
42. Backman JT, Kyrklund C, Kivisto KT, et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000;68:122-9 (Pubitemid 30659167)
43. Kyrklund C, Backman JT, Neuvonen M, et al. Gemfibrozil increases plasma pravastatin concentrations and reduces renal clearance. Clin Pharmacol Ther 2003;73:538-44 (Pubitemid 37249124)
44. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharamacol Ther 2004;75:455-63 (Pubitemid 38534566)
45. Zhou S, Chan SY, Cher Goh B, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005;44:279-304 (Pubitemid 40477790)
46. Peters BJM, Klungel OH, de Boer A, et al. Genetic determinants of response to statins. Expert rev Cardiovasc Ther 2009;7(8):977-83
47. Keskitalo JE, Zolk O, Fromm MF, et al. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2009;86:197-203
48. Keskitalo JE, Pasanen MK, Neuvonen PJ, et al. Different effects of the ABCG2 c.421C>A single nucleotide polymorphism on the pharmacokinetics of Fluvastatin, pravastatin, and simvastatin. Pharmacogenomics 2009;10:1617-24
49. Keskitalo JE, Kurkinen KJ, Neuvonen PJ, et al. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008;84(4):457-61
50. Peters BJM, Rodin AS, Klungel OH, et al. Pharmacogenetic interactions between ABCB1 and SLCO1B1 genes tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. Pharmacogenomics 2010;11(8):1065-76
51. Kajinami K, Brousseau ME, Ordovas JM, et al. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 2004;93(1):104-7 (Pubitemid 38022047)
52. Fiegenbaum M, da Silveira FR, van der Sand CR, et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005;78(5):551-8 (Pubitemid 41698910)
53. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009;158:693-705
54. Wilke RA, Lin DW, Roden D, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007;6(11):904-16 (Pubitemid 350042398)
55. Basic Concepts. In: Waller P, editor, An Introduction to Pharmacovigilance. Wiley-Blackwell, Oxford, UK; p. 15-29
56. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of 39 prospective studies. JAMA 1998;279:1200-05. (Pubitemid 28193431)
57. Limdi NA, Veenstra DL. Expectations, validity, and reality in pharmacogenetics. J Clin Epidemiol 2010;63:960-9
58. Guttmacher AE, Collins FS. Genomic medicine: a primer. N Engl J Med 2002;347:1512-20
59. Wang ET, Sandberg R, Luo S, et al. Alternative isoforms regulation in human tissue transcriptomes. Nature 2008;456:470-6 (Pubitemid 352759009)
60. Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA 2008;299:11 1335-44 (Pubitemid 351439079)
61. Nordin C, Dahl ML, Eriksson M, et al. Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphisms? Lancet 1997;350:29-30
62. Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997;7:193-202 (Pubitemid 27290633)
63. Mulder AB, van Lijf HJ, Bon MA, et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther 2001;70(6):546-51 (Pubitemid 34008412)
64. Zuccaro P, Mombelli G, Calabresi L, et al. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesterolaemic response to simvastatin and Fluvastatin. Pharmacol Res 2007;55:310-17 (Pubitemid 46518161)
65. Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 2003;56(1):120-4 (Pubitemid 36886497)
66. Quinzii C, Naini A, Salvatti L, et al. A mutation in para- hydroxybenzoatepolyprenyl transferase (CoQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet 2006;78:345-9 (Pubitemid 43157573)
67. Newman TB, Browner WS, Cummings SR, et al. Designing an observational study: cross sectional and case-control studies. In: Hulley SB, et al., editors, Designing clinical research: an epidemiologic approach. Lippincott Williams & Wilkins, Philadelphia; p. 107-24
68. Balding DJ. A tutorial on statistical methods for population association studies. Nature Reviews 2006;7:781-91 (Pubitemid 44413222)
69. Rotimi CN, Jorde LB. Ancestry and disease in the age of genomic medicine. N Engl J Med 2010;363:1551-8
70. Peters BMJ, Rodin AS, de Boer A, et al. Methodological and statistical issues in pharmacogenomics. JJP 2010;62:161-6
71. Hansen NT, Brunak S, Altman RB. Generating genome-scale candidate gene lists for pharmacogenomics. Clin Pharmacol Ther 2009;86:183-9
72. Romaine SPR, Bailey KM, Hall AS, et al. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J 2010;10:1-11
73. Pasanen MK, Fredrikson H, Neuvonen PJ, et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007;82(6):726-33 (Pubitemid 350114817)
74. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005;78(4):330-41 (Pubitemid 41393668)
75. Ho RH, Choi L, Lee W, et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics 2007;17(8):647-56 (Pubitemid 47057714)
76. Pasanen MK, Neuvonen M, Neuvonen PJ, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16(12):873-9 (Pubitemid 44772805)
77. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 2006;80:356-66 (Pubitemid 44465886)
78. Morimoto K, Ueda S, Seki N, et al. Candidate gene approach for the study of genetic factors involved in HMG-CoA-reductase inhibitors induced rhabdomyolysis [abstract]. Eighteenth JSSX Annual Meeting; 2003. p. 8PE-32
79. Morimoto K, Oishi T, Ueda S, et al. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab Pharmacokinet 2004;19(6):453-5
80. Morimoto K, Ueda S, Seki N, et al. OATP-C(OATP01B1) *15 is associated with statin-induced myopathy in hypercholesterolemic patientsOATP. Clin PharmacoTher 2005;77:P21
81. The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy - A genomewide study. N Engl J Med 2008;359:789-99
82. Voora D, Shah Sh, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16
83. Donnelly LA, Doney AS, Tavendale R, et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther 2011;89(2):210-16
84. Manolio TA. Genomewide association studies and assessment of risk of disease. N Engl J Med 2010;363:166-76
85. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97(Suppl):52C-60C
86. McGreechan K, Macaskill P, Irwig L, et al. Assessing new biomarkers and predictive models for use in clinical practice. Arch Intern Med 2008;168(21):2304-10
87. Kameyama Y, Yamashita K, Kobayashi K, et al. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet 2005;15:513-22 (Pubitemid 41017600)
88. Hirano M, Maeda K, Shitara Y, et al. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004;311:139-46 (Pubitemid 39287793)
89. Deng JW, Song IS, Shin HJ, et al. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics 2008;18:424-33 (Pubitemid 351535943)
90. Hsiang B, Zhu Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver specific human organic anion transporting polypeptide and identification of rat and human hydroximethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999;274:37161-8
91. Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004;76:167-77 (Pubitemid 39013406)
92. Ho RH, Tirona RG, Leake BF, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006;130:1793-806
93. Chen C, Mireles RJ, Campbell SD, et al. Differential interaction of 3-hydroxy-3- methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 2005;33:537-46 (Pubitemid 40393197)
94. Shitihara Y, Hirano M, Sato H, et al. Gemfibrozil and its glucorunide inhibit the anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004;311:228-36 (Pubitemid 39287802)
95. Noe J, Portmann R, Brun ME, et al. Substrate-dependent drug-drug interactions between gemfibrozil, Fluvastatin and other organic anion transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 2007;35:1308-14 (Pubitemid 47121771)